AMRI: Summary for Albany Molecular Research, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 8:18am EST - Canadian Markets open in 1 hour and 12 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Albany Molecular Research Inc. (AMRI)

On Feb 9: 8.46 USD 0.00 (0.00%)

MORE ON AMRI

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Albany Molecular Research, Inc. (NasdaqNM:AMRI) Delayed quote data

Last Trade:	8.46 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	8.46
Open:	N/A
Bid:	0.01 x 200
Ask:	9.40 x 100
1y Target Est:	15.00

Day's Range:	N/A - N/A
52wk Range:	7.31 - 11.31
Volume:	0
Avg Vol (3m):	79,355.6
Market Cap:	267.70M
P/E (ttm):	30.43
EPS (ttm):	0.28
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add AMRI to Portfolio

Download Data

HEADLINES

•	AMRI reports $19M net loss in 4Q
	at bizjournals.com (Mon, Feb 8)

•	ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
	EDGAR Online (Mon, Feb 8)

•	AMRI Announces Fourth Quarter 2009 Results
	Business Wire (Mon, Feb 8)

•	AMRI CFO to Present at UBS 20th Annual Global Healthcare Services Conference
	Business Wire (Tue, Feb 2)

•	AMRI to Announce Fourth Quarter Results
	Business Wire (Mon, Feb 1)

•	Research And Development Expenditures In Diagnostic And Lab Equipment Sector Raises Capital Requirements: Will Acquisitions By Larger Health Care Companies Be The Result?
	Wall Street Transcript (Wed, Jan 27)

•	AMRI CFO to Present at Jefferies 2010 Global Healthcare Services Conference
	Business Wire (Tue, Jan 19)

•	AMRI Receives SafeBridge® Potent Compound Safety Certification
	Business Wire (Tue, Jan 19)

•	AMRI CEO to Present at 28th Annual J.P. Morgan Healthcare Conference
	Business Wire (Thu, Jan 7)

•	Bruno name stays put in Capital Region
	at bizjournals.com (Wed, Dec 9)

More Headlines for AMRI...

ANALYST

EPS Est (next year) (Dec-07) :	0.32
EPS Est (in 2 years) (Dec-08) :	0.41
Avg Rec (current)*:	2.5
PEG Ratio:	1.68

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Albany Molecular Research, Inc., a drug discovery and development company, focuses on the identification and development of biologically active small molecules with applications in the drug market.

Full Company Profile

Add to Portfolio

Email to a Friend

•